Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07168356 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease
A Phase 1 study of Hepatitis B, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT07168356: Recruiting Phase 1 study of Hepatitis B, sponsored by GlaxoSmithKline.
NCT07168356 is a Phase 1 study of Hepatitis B that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 32 participants, below the 1,628-participant average among 32 other Hepatitis B trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07168356, a Phase 1 study of Hepatitis B, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 2-part study where all participants will receive bepirovirsen. The study will measure how much bepirovirsen from a single dose gets into the blood, and how long it stays in the blood. The purpose of the study is to understand if blood levels of bepirovirsen are different in adults with kidney disease compared to healthy adults who do not have kidney disease.
Conditions Studied
Interventions
- DRUG Bepirovirsen
Study Locations (1)
Florida
- GSK Investigational Site - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2026-08-18 |
| Phase | Phase 1 |
What NCT07168356 shows while recruiting
NCT07168356 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,628-participant average among 32 other Hepatitis B trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Hepatitis B appearing as the primary indexed condition, and to 1 intervention - of which Bepirovirsen is the first listed.
NCT07168356 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07168356 about?
NCT07168356 is a clinical study titled "A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease". This is a 2-part study where all participants will receive bepirovirsen. The study will measure how much bepirovirsen from a single dose gets into the blood, and how long it stays in the blood. The purpose of the study is to understand if blood levels of bepirovirsen are different in adults with kid...
What is the current status of trial NCT07168356?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-09-16. Estimated completion is 2026-08-18.
What conditions does trial NCT07168356 study?
This clinical trial studies the following conditions: Hepatitis B.
What interventions are being tested in trial NCT07168356?
The interventions under investigation include: Bepirovirsen (DRUG).
Who is sponsoring clinical trial NCT07168356?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07168356 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07168356's enrollment target sits among peer trials
32 24th of 32 higher than 8 of 32 other Hepatitis B trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis B trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B
RECRUITING · Phase 1
-
HepB mAb19 in Individuals With Chronic Hepatitis B Infection
RECRUITING · Phase 1
-
Simvastatin for the Treatment of Chronic Hepatitis B
COMPLETED · Phase 1
-
Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients
COMPLETED · Phase 1
-
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
COMPLETED · Phase 1
-
Evaluation of Patients With Liver Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI